72 Jane Street VW 
New York N Y 10014 - 
(212)675-7173 A 
Coalition for Responsible Genetic Research 
ADVISORY COUNCIL 
John S Bird M D 
Dr Irwin B'o» 
M«len Caldicott MO* 
Dr licbe Cavglieri* 
John C Cobb M D * 
Dr DougUi D«Nike 
Dr Key Dumukei* 
W lack Frumm M D 
Solomon Carb M D * 
Stev«n Hjvd M D * 
Or Ruth Hubbard* 
Dr Marvin Kjlkslem* 
J R Kent M D 
Dr Jonathan King* 
Dr Sheldon Knmiky* 
Elliot linier* 
Pamela Lippe’ 
Joyce Milton 
Lewii Mumford* 
Dr Stuart Newman* 
Christine Oliver MO* 
David Oionolf MO* 
Dr Barbara Rotenberg’ 
David Straton MO* 
Dr Ceorge Wald*. 
Nobel Laureate 
Suunna Waterman* 
Or Joseph Weirenbaum* 
Or Sutan Wnght* 
*£*ecutive Committee 
MEMBERSHIP 
PARTIAL IISTINC 
Walter Aikinai M D 
David R Brower 
Rev Roger Burgeti 
Sir MacFarlane Burnet. 
Nobel Laureate 
Stuart Chate 
Citirent Rights Committee 
Glen C Cobb M D 
Dr C David Elm 
William D Furst M D 
Reverend David A Furunest 
Mariano L Calameva M 0 
W B Gamble Jr M D 
F M Colo mb M 0 
Dr Mario A Conialea 
Harold J Hams M D 
Dr Kenneth l Jackson 
Father Walter T Kelleher 
Hadley Kirkman M D 
Or Laura Krata 
Henry O lauson M D 
Dr Herbert Manning 
Edwm F Matthews |r 
Edward Miller M O 
Robert Murphy M D 
Maurice l Ongenes M D 
Or Aurelio Peccei ' 
Henry Pinkerton M D 
Eliot Porter 
Dr Jerome Prager 
Dr Steven Price 
Srster Mary E Reichert 
Abby Rockefeller 
lewis M Schiffer M D 
Solomon Garb M D 
Membership Secretary 
Francine R Simnng 
Eaecufrve Director 
V 
§ 
(§ 
§ 
p' 
I 
COMMENTS ON PROPOSED REVISED GUIDELINES FOR 
RECOMBINANT DNA RESEARCH 
FEDERAL REGISTER, JULY 28, 1978 
PART IV 
1HTR0VUCT10N 
To date, the bulk of recombinant DNA research has been 
funded by government agencies and has been carried out on a 
small scale. However, the character of a significant pro- 
portion of the work is likely to change if commercial inter- 
est in the field continues to expand: 
1. A goodly proportion of recombinant DNA act- 
ivities will not be subject to the sanction of with- 
drawal of government funding (at present, one of the 
main mechanisms for control). 
2. There will be growing pressure to scale up 
culture volume and to release organisms containing re- 
combinant DNA into the environment in preparation for 
commercial application. 
As the guidelines acknowledge, social considerations will con- 
tribute to decisions in those areas (p. 33070, Col. 1). 
Therefore, the present review of the proposed revised 
guidelines by the Department of Health, Education, and Welfare 
is particularly well-timed for consideration pf changes to 
ameliorate the following problems: 
0 the partisan structure of the NIH Recombinant 
DNA Advisory Committee 
0 the potential conflicts of interest implicit in 
regulation by the NIH whose function is to promote 
and f und 
0 lack of apparatus for effective treatment of social 
and regulatory questions posed by recombinant DNA 
activities 
[A-283] 
